Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Neoadjuvant treatment before radical prostatectomy: Current situation

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 472

Prof Nicolas Mottet - University Hospital St Etienne, St Etienne, France

Prof Nicolas Mottet speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the neoadjuvant treatment prior to surgery in patients with prostate cancer.

Prof Mottet describes the types of neoadjuvant therapy which consists of either oral treatment or a combination of oral treatment plus chemotherapy.
The use of bicalutamide as an oral therapy has shown little added value, however newer drugs such as enzalutamide and abiraterone have shown limited data thus far.

In regard to the combination of docetaxel and ADT along with local treatment, Prof Mottet notes one French trial which achieved an improvement in progression-free survival, however this did not translate with metastasis-free or overall survival.

Prof Mottet also emphasises that this data is purely experimental at this stage and that neoadjuvant ADT should not be used prior to surgery - as stated in the recommended guidelines.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation